Abraxis BioScience Inc. said Thursday it and a marketing partner had received regulatory approval to sell the breast cancer treatment Abraxane in India.

The U.S. Food and Drug Administration approved Abraxane in January 2005, and recent gave the go-ahead for a study that could expand its use to treating lung cancer. The drug had sales of $174.9 million last year, according to the company.

Lo Angeles-based Abraxis will be working with a major Indian biopharmaceutical company, Biocon Ltd., which holds the rights to sell Abraxane in that country. The drug is expected to launch there next year.

Abraxis has Abraxane applications pending in several Asian and Persian Gulf nations. In a separate announcement Thursday, the company said a European Union regulatory advisory committee had endorsed its application there.

On Wednesday, the company announced that it had received its second approval this month to market a generic version of a Pfizer Inc. chemotherapy drug. A generic version of Ellence is expected to launch by the end of the year.

A generic version of Camptosar should hit the market after Pfizer’s patent expires in February.

Shares of Abraxis were down 40 cents, or 1.7 percent, to $23.61 in afternoon trading in the Nasdaq exchange.